Noninfectious nonerosive arthritis in two dogs

Two cases of noninfectious, nonerosive arthritis are presented. The diagnostic features, clinical course and treatment are reviewed. Potential etiologies are discussed in the light of relatively little current material on this subject in the veterinary literature.     

Pemphigus and pemphigoid in domestic animals: an overview

Pemphigus and pemphigoid are uncommon dermatological entities in domestic animals and of a presumed autoimmune nature. In one form or another, they have been reported in the dog, cat, horse and goat. Although these diseases are considered to be bullous dermatoses, the clinical presentation may vary from ulcerative to exfoliative to proliferative depending on the individual condition. Currently, four variants of pemphigus are recognized (vulgaris, vegetans, foliaceus, erythematosus) and two of pemphigoid (bullous, cicatricial) although cicatricial pemphigoid has not yet been conclusively demonstrated in animals. Diagnosis is based on history, clinical signs, histopathology and immunopathology. Therapy must be immunosuppressive to be effective and is palliative rather than curative.     

Caprine beta-Mannosidosis in Kids from an Ontario Herd

Caprine β-mannosidosis, a fatal inherited deficiency of the lysosomal enzyme β-mannosidase, was diagnosed in neonatal female Nubian crossbred twin kids from a small herd near Guelph, Ontario. The kids had been tetraplegic since birth, with whole body tremors, abnormal nystagmus and an intention tremor of the head.     

Origin of espanola island and the age of terrestrial life on the galapagos islands

Geological studies of Espa?ola (Hood) Island, Galápagos, Ecuador, indicate that the island had a subaerial rather than a submarine origin. Because the younger lava flows are dated at 3 million years, Espa?ola has apparently existed as an island for at least that long. Thus terrestrial life may have existed or arrived on the Galápagos Islands at least 3 million years ago, more than twice as long as had been assumed.     

A fossil noctuid moth egg from the late cretaceous of eastern north america

A moth egg assignable to the family Noctuidae (Lepidoptera) is described from 75-million-year-old sediments from Martha's Vineyard, Massachusetts. This sample, which extends the fossil record of this farnily and modern heteroneuran moths back to the Cretaceous, may provide insight into the coevolution of moths and flowering plants, as well as have implications for the evolution of bats.     

Fenbendazole treatment of pregnant bitches to reduce prenatal and lactogenic infections of Toxocara canis and Ancylostoma caninum in pups

A granulated formulation of fenbendazole was tested in a total of 23 treated and control, pregnant, parasite-free Beagle bitches experimentally infected with Toxocara canis and Ancylostoma caninum. The drug was administered to each treated bitch once daily in canned dog food at a dosage of 50 mg/kg body weight. Each of 2 treatment regimens tested was initiated on the 40th day of pregnancy. One regimen involved daily treatment continuing through the 14th postpartum day, and it resulted in 89% fewer ascarids and 99% fewer hookworms in pups born to medicated bitches, as compared with pups born to unmedicated controls. The other regimen of treatment, which was stopped on the day of parturition, was less effective in reducing ascarid and hookworm burdens (64% and 88% reductions, respectively). Three to 5 bitches from each of the treatment and control groups were allowed to whelp a 2nd litter without further treatment or further exposure to parasite infections. Hookworm burdens in 2nd-litter pups born of bitches that had initially received fenbendazole through the 14th postpartum day were significantly lower (P < 0.01; 85% reduction), when compared with the 2nd-litter control pups. All other parasite burdens were not significantly different. It was concluded that granulated fenbendazole is effective in reducing burdens of Ancylostoma caninum and Toxocara canis in newborn pups when the bitch is treated during the last third of pregnancy, especially when treatment (50 mg/kg/day) extends from the 40th day of pregnancy through the 14th postpartum day.